



41

\$ 1617
PTO/SB/21 (08-03)

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number	10/091,744
		Filing Date	March 5, 2002
		First Named Inventor	Holman, Andrew
		Art Unit	1617
		Examiner Name	T. Criares
Total Number of Pages in This Submission	1	Attorney Docket Number	020862-000110US

RECEIVED
JAN 16 2004
TECH CENTER 160012900

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input checked="" type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Response to Restriction Requirement; Return Postcard
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Townsend and Townsend and Crew LLP Mark G. Sandbaken, Ph.D. Reg. No. 39,354
Signature	
Date	Jan. 9, 2004

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Jennifer M. Smolen		
Signature		Date	Jan. 9, 2004

I hereby certify that this correspondence is being deposited with the
United States Post Office first class in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on

By: _____



PATENT

Attorney Docket No.: 020862-000110US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

ANDREW HOLMAN

Application No.: 10/091,744

Filed: March 5, 2002

For: ADMINISTRATION OF SLEEP
RESTORATIVE AGENTS

Examiner: T. Criares

Art Unit: 1617

**RESPONSE TO RESTRICTION
REQUIREMENT
AND AMENDMENT**

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This communication is submitted in response to the Restriction Requirement dated October 9, 2003, in which the Office further requires election of species with previously elected Group I, claims 1-29.

Response to Restriction Requirement begins on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks begin on page 9 of this paper.

Response to Restriction Requirement

Applicant elects to prosecute the following species, with traverse:

Method: Applicant elects "Group I," characterized as generally drawn to a method of sparing an effective amount of a therapeutic agent administered to a subject having rheumatoid arthritis by administering a therapeutic agent and an effective amount of a sleep restorative agent.

Sleep Restorative Agent: Applicant elects pramipexole (2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzo-thiazole or the (-)-enantiomer thereof), as set forth in claim 9.

Therapeutic agent: Applicant elects prednisone.

Claims 1-9, 13, 15-22, 24-26, 28-29 and new claims 40-45 read on the elected species.

Applicant reserves the right to file a divisional or related application to the claims of non-elected groups and species, as necessary: